Abzena and UGA Biopharma partner to develop a cell line expressing a biosimilar therapeutic for Multiple Sclerosis

October 27, 2017 11:49 AM

 

abzena-logo-biosimilarnews-uga-biopharma-logo
Abzena plc and UGA Biopharma GmbH announced the completion of the development of a biosimilar cell line to treat Multiple Sclerosis (MS).

Abzena, the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, partnered with UGA Biopharma, , a cell line development specialist and this partnership centred around the development of an NS0 (murine myeloma) manufacturing cell line, expressing a high quality, fully biosimilar antibody therapeutic. The cell line was developed and validated using Abzena’s integrated expert knowledge in cell line development and bioanalytics and was guided by UGA Biopharma’s in-depth knowledge and experience in the development of cell lines for biosimilar drugs.

UGA will join an expanding field of companies looking to capitalise on the patent expiry of several blockbuster drugs over the coming years.

The originator therapeutic is undisclosed but it is currently being used in the treatment of MS. It had worldwide sales of approximately $1.9bn in 2016.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!